Markkinen et al

1 Gene deletions in complement factor H related protein gene locus and kidne	1	Gene deletions	n complement	: factor H related	protein gene	locus and kidne
------------------------------------------------------------------------------	---	----------------	--------------	--------------------	--------------	-----------------

- 2 transplantation
- 3 Running title: CFHR deletions in kidney transplantation
- 4 Markkinen Salla^{1†}, Lokki Inkeri^{2,3†}, Helanterä Ilkka⁴, Ritari Jarmo¹, Partanen Jukka¹, Meri
- 5 Seppo^{2,5}, Hyvärinen Kati^{1,*}

6

- 7 ¹Research and Development, Finnish Red Cross Blood Service, Helsinki Finland
- 8 ²Translational Immunology Research Program, Department of Bacteriology and Immunology, Faculty
- 9 of Medicine, University of Helsinki, Helsinki, Finland
- ³Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
- ⁴Transplantation and Liver Surgery, Helsinki University Hospital and University of Helsinki, Helsinki,
- 12 Finland
- 13 ⁵Diagnostic Center, Helsinki University Hospital, Helsinki, Finland
- 14
- 15 ⁺ These authors contributed equally to this work
- 16
- 17

18

- 19 ^{*}Corresponding author
- 20 Ilkka Helanterä, MD, PhD, Associate professor
- 21 Helsinki University Hospital and University of Helsinki
- 22 Transplantation and Liver Surgery
- 23 PO Box 340, 00029 HUS, Helsinki, FINLAND
- 24 Phone +358 50 4279526
- 25 ilkka.helantera@helsinki.fi

Markkinen et al

27 ABSTRACT

28 We recently reported that a homozygous deletion in the complement factor H related 29 (CFHR) protein gene locus predisposed kidney transplant patients to allograft rejection. As 30 donors carried normal functional genes in the locus, the susceptibility may have resulted from alloimmune reaction to CFHR proteins. However, we found no evidence for anti-CFH 31 32 response in the patients. It is therefore possible that the CFHR gene deletions and 33 consequent protein deficiencies as such affect the rejection risk. Using multiplex ligation-34 dependent probe amplification method and genome sequencing, we confirmed that all 15 35 patients homozygous for rs7542235 GG, a SNP tagging the CFHR321 deletion had deletions of various sizes that invariably encompassed the whole of CFHR1 gene. The lack of CFHR1 36 37 protein in patient plasma samples was also demonstrated by Western blotting. Plasma 38 proteomics analyses of biobank samples demonstrated that rs7542235 allele G associates 39 with significantly changed expression levels of 23 proteins (FDR < 0.010). These proteins are 40 involved in various pathways, including regulation of alloimmune response and their roles in transplantation outcome merit further studies. Although CFHR gene abnormalities have 41 42 been associated with kidney diseases, we observed no clinical characteristics shared by or 43 enriched in patients homozygous for CFHR1 deletion. This suggests that the deletion as such 44 was not enriched in a baseline disease in this subgroup with a high risk for rejection. To conclude, the different deletion types found in patients shared the complete deletion of the 45 CFHR1 gene pointing to its primary role. Plasma proteomics studies show that deletion-46 47 tagging allele is associated with altered expression of CFH/CFHR proteins.

Markkinen et al

48 INTRODUCTION

49 Prior matching of human leukocyte antigen (HLA), ABO blood group types, and a negative 50 anti-HLA cross-matching are the golden rule in kidney transplantation. Regardless, some of 51 the patients still experience complications after kidney transplantation. In search of novel histocompatibility factors, a study by Steers *et al.*(1) reported that a homozygous gene 52 53 deletion of *LIMS1*, and our previous study (2) reported that homozygous gene deletion in 54 the CFH locus consisting of genes coding for complement factor H (CFH) and CFH related 55 proteins (CFHRs) were associated with acute rejection of the graft. There are a few mutually non-exclusive mechanistic explanations to these findings. The rejection may be related to 56 57 alloimmune response by the patient against the protein missing from the patient but 58 expressed by the graft, hence, as such not necessarily linked to the function of the protein. 59 Alternatively, the rejection risk may be related to the function of the protein missing from the patient. The functional effect can be direct, i.e., a result of the missing protein, or 60 61 caused by expression of the missing protein by the transplanted kidney, or it can be related 62 to complex downstream networks. A deletion of a gene and adjacent DNA segments may 63 furthermore lead to changes in the expression of some other genes that can be identified, for example, using quantitative trait loci (QTL) (3–5) approaches. Steers and co-workers, 64 65 who reported association between *LIMS1* gene deletion and graft rejection in kidney transplantation could identify a specific anti-LIMS1 antibody pointing to alloimmune 66 67 response against the LIMS1 protein missing from the patient. In our recent study (2), we could not replicate the *LIMS1* deletion association in the set of 1025 Finnish kidney 68 69 transplantation patients and donors, but instead reported an association between CFHR 70 locus deletion and graft rejection. The CFHR locus contains genes encoding for CFH, a major regulator of the alternative pathway (AP) of complement activation, and a set of related 71 72 genes, CFHR1-5 (2,6). CFH inhibits AP activation both in body fluids and on cell surfaces. It 73 binds to C3b, which has become bound to self surfaces, where it inhibits local complement 74 activation. In contrast, on "foreign" targets, like microbial or virus surfaces binding of CFH to surface deposited C3b is weak (7–9). The functions of CFHR1–5 proteins are becoming 75 76 better understood. As suggested already a long time ago (10) the CFHRs are known to 77 promote complement activity by competing with the master inhibitor CFH (6). Genetic 78 variants of CFH and CFHR1-5 have been linked to the pathogenesis of some kidney diseases,

Markkinen et al

4

such as C3 glomerulopathy (11), atypical hemolytic uremic syndrome (12,13) and IgA
nephropathy (14). In the present study, we wanted to understand the effects of *CFHR3–1*gene deletions in detail. We fine-mapped the deletion boundaries using multiple ligationdependent probe amplification (MLPA) and whole genome sequencing (WGS). We found
that deletions of various sizes shared a homozygous deletion of *CFHR1* gene. Proteomics of
plasma samples revealed that, in fact, the deletion-tagging allele resulted in plasma protein
level changes of at least 23 proteins. This shortlist merits further studies.

86

87 MATERIALS AND METHODS

88 Study cohort

89 The present study included 15 patients from the study of Markkinen et al. (2), who had 90 rs7542235 GG-genotype tagging for the homozygous deletion in the *CFHR3–1* locus. The 91 patients received their first kidney transplantation during 2007–2017 at the Helsinki 92 University Hospital, Helsinki, Finland. The characteristics of the whole study population 93 including the 15 patients with homozygous CFHR3-1-deletion tagging variant (GG) and 1010 94 patients with heterozygous (AG) or homozygous non-deletion genotype (AA) are presented 95 in **Table 1**. In total of 199 (20%) rejections were observed in our study cohort. The primary 96 outcome for these patients was biopsy-proven acute rejection, including both antibodymediated and T-cell-mediated rejections (15). Borderline changes were also included as 97 98 rejections. The characteristics of the 15 patients (8 in the rejection-group and 7 in the nonrejection-group) with CFHR3–1-deletion tagging rs7542235 GG-genotype are presented in 99 100 Table 2.

DNA samples were extracted from whole blood at the time of histocompatibility testing for
 transplantation, and serum samples were collected for complement-dependent cytotoxic
 crossmatch to detect alloantibodies before and after transplantation at the Finnish Red
 Cross Blood Service, Helsinki, Finland.

The clinical data were extracted from the Finnish Transplant Registry, which is a national
follow-up registry obliged by law (Table 1).

Markkinen et al

107

108 Genotyping and imputation

- 109 Genotyping and imputation procedures are explained in more detail in Markkinen et al. (2).
- 110 Briefly, the genotyping was performed at the Finnish Institute of Molecular Medicine
- 111 (FIMM), Helsinki, Finland using Illumina's Infinium Global Screening array-24 v2.0 with multi-
- disease drop-in. The genotyped data were imputed with Finnish SISu v3 reference panel
- 113 consisting of high-coverage WGS data from THL Biobank cohorts (N=1768) (Pärn et al.
- 114 manuscript in preparation). The variants rs7542235 tagging for CFHR-deletion was imputed
- and had an estimated quality measurement value, INFO-score, of 0.98.
- 116

117 Multiplex ligation-dependent probe amplification

- 118 MLPA was performed for 15 homozygous rs7542235 GG patients (eight with rejection,
- seven without rejection) to screen the copy number variations in *CFH/CFHR* genomic region.
- Additionally, we performed the analysis for control patients including eight individuals with
- 121 heterozygous AG-genotype (four with rejection, four without rejection) and eight individuals
- 122 with homozygous AA-genotype (four with rejection, four without rejection). The detailed
- description of MLPA procedure is provided in the **Supplementary data**.

124

125 Whole genome sequencing

126 WGS was previously performed for three rs7542235 GG patients with rejection. The results and detailed information about the WGS for these samples are provided in the main text 127 and supplementary data of our previous publication (2). Here, we sequenced seven more 128 129 patients with GG-genotype (five with rejection, two without rejection). Sequencing was 130 performed at FIMM, Helsinki, Finland, and the samples were sequenced with Illumina's NovaSeq S4 NS4-300 run. The number of aligned bases for each sample was 20–50 Gb. The 131 input reads for each sample were around 200–500 million, and the length of reads was 151 132 base pairs. The coverage depth for the sequenced samples was 7–17x. More detailed 133 134 statistics for the WGS run are presented in **Supplementary Table S2**.

Markkinen et al

135

136 Western blot for CFH/CFHR proteins

- 137 In total of 15 serum samples from nine rs7542235 GG patients (five with rejection, four
- 138 without rejection) were available for western blot analysis of CFH, CFHR1 and CFHR2
- expression. From the 15 serum samples, nine were collected before transplantation (pre-tx)
- and six were collected after transplantation (post-tx). The detailed methods for western blot
- 141 are provided in the **Supplementary data**.

142

143 Expression quantitative trait loci (eQTL) analyses

- 144 In the eQTL analyses, we used three databases to see the impact of CFHR3-1 deletion
- 145 tagging variant rs7542235 to gene expression: 1) The FIVEx browser
- 146 (https://fivex.sph.umich.edu/) eQTL data from blood vessel and kidney samples from the
- 147 EBI eQTL catalogue (4); 2) the eQTLGen Consortium database (https://www.eqtlgen.org/)
- including cis-eQTL, trans-eQTL and eQTS (associations between polygenic scores and gene
- expression levels) data from 37 datasets (3) from blood samples; and 3) the Human Kidney
- 150 eQTL Atlas (https://susztaklab.com/Kidney eQTL/index.php) including four studies with
- 151 total of 686 microdissected human kidney tubule samples (5). Each of these three databases
- share data from the Genotype-Tissue Expression Consortium (GTEx). All the results are
- 153 included.

154

155 Protein quantitative trait loci (pQTL), gene ontology and Reactome analyses

- 156 We used Olink (n = 1225) and SomaScan (n = 865) pQTL plasma proteomics data of healthy
- 157 blood donors from FinnGen project (https://www.finngen.fi/en) to see whether the
- 158 CFHR3 21 deletion tagging variant rs7542235 has effect on protein expression. False
- detection rate (FDR) of <0.010 were considered statistically significant. The genes with FDR
- 160 <0.010 were included in the gene ontology (GO) enrichment analysis
- 161 (<u>https://geneontology.org/</u>) for each three aspects of biological process, molecular function
- and cellular component, and Reactome pathway database (<u>https://reactome.org/</u>).

Markkinen et al

163

164 Other statistical analyses

165	Characteristics of patients in Table 1 and Table 2 were described by medians and
166	interquartile ranges (IQRs) or ranges, and frequencies and percentages. The comparison
167	between the two groups of patients with rs7542235 GG-genotype and patients with AA/AG-
168	genotype (Table 1), and GG-genotype with rejection and GG-genotype without rejection
169	(Table 2) were analyzed using the nonparametric Mann-Whitney U-test for non-normally
170	distributed data (recipient age, follow-up time, PRA I and II, HLA eplet mismatch, HLA I eplet
171	mismatch and HLA II eplet mismatch), Pearson's chi-square test for recipient sex, Fisher's
172	exact test for primary diagnosis, or Student's t-test for normally distributed data (cold
173	ischemia). The significance of variation of PRA-values in Table 2 was not analyzed due to the
174	low frequency count. P-values <0.05 were considered statistically significant.

175

176 RESULTS

177 Characteristics of the study population

We previously reported genetic association between reduced rejection-free survival and *CFHR3*¹-deletion tagging variant rs7542235 genotype GG (2). 15 out of 1025 patients were
homozygous for this deletion-tagging variant, 4% belonging to rejection-group and 1% to
non-rejection group.

182 The characteristics of the study groups are shown in **Table 1** and **Table 2**. In total of 53% of 183 rs7542235 GG patients had rejection, whereas the percentage among AG/AA patients was 184 only 19 (P-value < 0.001). Also other diagnoses are more common among patients with 185 AG/AA patients than in the GG genotype group (P-value <0.001). The primary diagnosis of 186 hydronephrosis with ureteropelvic junction obstruction is significantly different between the 187 rs7542235 GG and AG/AA patients with P-value of 0.029 (Table 1). No significant difference 188 in characteristics between those with rejection and without rejection among patients with 189 rs7522235 GG genotype were found (Table 2). There was no enrichment of diagnoses 190 known to be linked to CFHR locus.

Markkinen et al

191

192 Multiplex ligation-dependent probe amplification

- 193 MLPA confirmed that all 15 rs7542235 GG patients had homozygous deletions of different
- sizes at the *CFH/CFHR* locus, three different types are depicted in the **Figure 1**. The shared
- 195 feature of all samples was a homozygous deletion of *CFHR1* gene.
- 196 As assumed, eight patients with rs7542235 genotype AA had no deletions at the CFHR locus,
- and eight patients with heterozygous AG genotype carried a heterozygous deletion
- 198 encompassing both the *CFHR1* and *CFHR3* genes (Figure 2).
- 199

200 Whole genome sequencing

201 WGS (Figure 3) confirmed the results of MLPA; all seven rs7542235 GG patients had

202 homozygous deletions of different sizes but they shared the deletion of the CFHR1 gene

203 (Supplementary Figure S1). In addition to homozygous deletions, WGS results confirmed

the findings of MLPA results showing that 5 out of 10 patients carried heterozygous

205 deletions (Figure 3C and D).

206

207 Western blot of CFH/CFHR proteins

208 The western blot run showed that 9/9 of serum samples from individuals with rs7542235

209 GG genotype lacked the CFHR1 protein (Figure 4). The results are in line to those obtained

- from genetic MLPA and WGS analyses. The more detailed description and genotypes for
- 211 each serum sample is shown in **Table 3**.
- 212

213 Expression quantitative trait loci analyses

- To understand whether the gene deletions or the tagging variant rs7542235 regulates the
- expression of other genes we screened the eQTL databases for rs7542235. The results are
- presented in Table 4. When searching for the CFHR3–1 deletion-tagging variant rs7542235
- 217 from the FIVEx database, the allele G was associated with the lower expression levels of

Markkinen et al

9

218 CFHR1, -3, and -4 genes. All the results from FIVEx were from GTEx study, including data 219 from blood vessel and kidney samples. Based on the eQTLGen Consortium database consisting of only blood samples, rs7542235 G was associated merely with the higher 220 expression level of CFH, with a Z-score of 10.05 and P-value of 8.88 x 10⁻²⁴. When screening 221 the Human Kidney eQTL Atlas having samples from kidney tubule, we found two statistically 222 significant associations in genes CFHR1 and CFHR3, with P-values of 2.73 x 10⁻⁵⁸ and 4.01 x 223 10⁻¹⁰, respectively. The beta-values for these findings were negative indicating reduced 224 225 expression.

226

227 Protein quantitative trait loci, gene ontology and Reactome analyses

228 When analysing the effect of variant rs7542235 allele G on protein expression, in total of 23 229 proteins were shown to be differentially expressed. The Olink results showed three genes to 230 be associated with the CFHR-deletion tagging variant with FDR <0.010; CFH, CFHR2 and 231 CFHR5 (Table 5), each of having positive beta-value and thus meaning an increase in 232 expression. SomaScan data resulted in total of 22 proteins to be differentially expressed 233 with FDR <0.010. In concordance to Olink results, also SomaScan showed an increase in 234 expression for CFH and CFHR5, and as was assumed, the CFHR321 deletion tagging variant 235 resulted in decreased expression of CFHR1 gene. Other differentially expressed genes with 236 FDR <0.010 included, e.g., prolactin receptor (PRLR) with decreasing expression levels and 237 Kirre Like Nephrin Family Adhesion Molecule 1 (KIRREL1) with increased expression. In the 238 GO enrichment analysis of molecular function annotation, four out of 23 genes (CFH, CFHR1, 239 CFHR2 and CFHR5) were associated to three functions of complement component C3b binding, opsonin binding and complement binding with FDRs 8.06 x 10^{-6} , 3.71 x 10^{-5} and 5.34 240 x 10⁻⁵, respectively (**Supplementary table S4**). The Reactome pathway analysis showed that 241 four out of 23 genes (CFH, CFHR1, CFHR2 and CFHR5) were associated to two pathways; 242 regulation of complement cascade and complement cascade with FDR 1.00 x 10⁻³ for both 243 244 (Supplementary table S4).

Markkinen et al

246 DISCUSSION

247 We reported earlier that homozygosity for variant rs7542235 allele G, tagging deletions at 248 the *CFHR3–1* locus, predisposed patients to kidney allograft rejection. To understand better 249 the mechanisms behind the association, we here fine-mapped the deletion boundaries and 250 studied the effects of the gene deletion on protein levels. Our results show that kidney 251 transplantation patients with GG genotype of deletion-tagging variant rs7542235 have gene 252 deletions of various sizes and types in the *CFHR* locus. The different deletion types, 253 however, shared the complete deletion of the *CFHR1* gene pointing to its primary role. The 254 lack of expressed CFHR1 protein in homozygotes could be confirmed by Western blot 255 analysis. We also showed by using both eQTL databases and proteomics studies that the 256 rs7542235 allele G is associated with differences in plasma expression levels of various 257 proteins, not merely with those encoded by genes at the CFH/CFHR locus but others as well. It is of note that the patients having the homozygous *CFHR1* deletion did not share any 258 259 particular type of kidney disease. This is understandable, because e.g., C3 glomerulopathy or 260 CFHR5 nephropathy are known to be associated with an increased rather than decreased 261 activity of the CFHR proteins. The increased activity is assumed to be due to a tendency to 262 make dimers that more efficiently compete with CFH. Only an autoimmune form of 263 haemolytic uremic syndrome, with autoantibodies against CFH, is linked to CFHR3-1 264 deficiency. The spectrum of kidney diseases in patients with homozygous *CFHR1* deletion 265 was typical to adults receiving a kidney transplant in Finland. It did not involve complementmediated diseases. 266

267 As mentioned above, a deletion in the CFHR3-1 locus may promote formation of anti-CFH 268 antibodies (13,16). Our previous results showed that there were no *de novo* anti-CFH 269 antibodies detected from serum samples of patients with rs7542235 GG genotype receiving 270 a graft from a donor of either AG or AA genotype. This suggests that the deletion itself 271 might not lead to alloimmune response, but could as such explain the association with 272 rejection or even with the primary diseases of the patients. However, the possibility that 273 CFHR1 could become the target of cell-mediated immunity has not been excluded. 274 Sequence and copy number variations in the human CFH and CFHR1-5 gene cluster have

been linked to the kidney disorders such as C3 glomerulopathy (11), and IgA nephropathy

Markkinen et al

11

276 (14). It has been shown that homozygous deletion and deficiency of CFHR3-1 has a 277 protective effect in IgA nephropathy (17) and age-related macular disease (AMD) (18). A 278 hybrid form of the CFHR3-1 gene has been associated with an increased risk for C3 279 glomerulopathy (11). This finding indicates that an overactivity of CFHRs is linked to 280 complement-mediated diseases. 281 A recent study by Sun *et al*. discovered that a mismatches in *LIMS1* was associated with 282 death-censored graft loss, and are in expression quantitative trait loci in immune cells for 283 GCC2, a gene encoding for a protein involved in mannose-6-phosphase receptor recycling 284 and thus possibly triggering immune responses in the recipient (19). As shown by the eQTL and pQTL results, it is plausible that the homozygous deletion of CFHR1 shared by all 285

patients influences the expression levels of other *CFHR* genes and proteins, and thus could

alter the complement activation. The variant rs7542235 allele G is associated with an

increased protein expression of CFH and decreased expression of CFHR1. While CFH inhibits

complement activation and protects human endothelial cells, CFHR1 has an opposite effect.

290 CFH is a regulator of the C3 convertase and promotes degradation of C3b and opsonization

of foreign pathogens with iC3b that results in phagocytosis. CFHR1 competes with CFH for

these activities, thereby increasing complement activation. It thus indirectly promotes

293 C3/C5 convertase activity and complement membrane attack complex assembly. By

inhibiting CFH binding to C3b, CFHR1 promotes C5a formation and consequent

inflammation. In the absence of CFHR1 and CFHR3, local CFH binding and activity would be

296 increased, resulting in suppression of complement activation, but, on the other hand,

297 possibly also to an impaired ability to handle injured tissue components.

The capillaries of kidney glomerulus are continually perfused by large volumes of blood, so the CFH/CFHR complement proteins present in plasma are in direct contact with the membrane. Due to filtration of water into urine, the concentration of complement proteins increases as plasma flows through the kidney, thus exposing these glomerular cells and surfaces to higher concentrations of CFH/CFHR proteins than are found elsewhere in the body. This could explain why kidney is relatively sensitive to any complement deficiencies.

304 (20)

Markkinen et al

12

305	Other differentially expressed genes based on proteomics data included <i>PRLR</i> and <i>KIRREL1</i> .
306	Prolactin (PRL) is an endocrine hormone that has several physiological effects including
307	immune system regulation and anti-inflammatory effects. It can trigger the production of
308	proinflammatory cytokines, also having several anti-inflammatory effects that can reduce
309	hyperinflammation (21). Prolactin exerts its effects through PRL receptors (PRLRs). KIRREL1,
310	also known as NEPH1, is a member of the NEPH protein family and is expressed in kidney
311	podocytes, cells involved in ensuring size- and charge-selective ultrafiltration. Mutations in
312	KIRREL1 gene has been linked to hereditary nephrotic syndrome.(22)
313	In conclusion, we found that patients with rs7542235 GG genotype shared a homozygous

deletion of the CFHR1 gene. Our plasma proteomics studies also show that deletion-tagging

- allele G is associated with altered expression of CFH/CFHR proteins and might thus be
- 316 involved in regulation of complement system.
- 317

318 AUTHOR CONTRIBUTIONS STATEMENT

319 S. Markkinen, J. Partanen and K. Hyvärinen planned the study, interpreted the results and

320 drafted the manuscript; S. Markkinen, I. Lokki and K. Hyvärinen carried out the genome data

321 analyses; the MLPA and western blot analyses and interpretation of the results of these

322 methods were carried out by I. Lokki, S. Markkinen and S. Meri; S. Markkinen executed in

323 silico database searches; J. Ritari combined the pQTL summary statistics; I. Helanterä

provided clinical data and expertise; all authors contributed to the final version of the

- 325 manuscript.
- 326

327 CONFLICT OF INTEREST STATEMENT

328 The authors have no conflicts of interest to declare.

329

330 ACKNOWLEDGEMENT

331 We want to thank Maria Semenova, BSc, for help in collecting the serum samples. We also

332 want to thank Lauri Snellman, biotechnology engineer, for help in laboratory with MLPA,

Markkinen et al

333	and Marcel Messing, PhD, for help with the western blot method. The THL Biobank's SISu v3
334	Imputation reference panel used for the research were obtained from THL Biobank (study
335	number: BB2019_12). We thank all study participants for their generous participation in
336	biobank research. We also want to thank the Sequencing Informatics Team, FIMM Human
337	Genomics, University of Helsinki for the WGS analyses. We want to acknowledge the
338	participants and investigators of FinnGen study. The FinnGen project is funded by two
339	grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following
340	industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb
341	(and Celgene Corporation & Celgene International II Sàrl), Genentech Inc., Merck Sharp &
342	Dohme LCC, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US
343	Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, Novartis Pharma AG, and
344	Boehringer Ingelheim International GmbH. Following biobanks are acknowledged for
345	delivering biobank samples to FinnGen: Auria Biobank (www.auria.fi/biopankki), THL
346	Biobank (<u>www.thl.fi/biobank</u>), Helsinki Biobank (<u>www.helsinginbiopankki.fi</u>), Biobank
347	Borealis of Northern Finland (<u>https://www.ppshp.fi/Tutkimus-ja-</u>
348	opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx), Finnish Clinical Biobank
349	Tampere (<u>www.tays.fi/en-</u>
350	US/Research and development/Finnish Clinical Biobank Tampere), Biobank of Eastern
351	Finland (<u>www.ita-suomenbiopankki.fi/en</u>), Central Finland Biobank (<u>www.ksshp.fi/fi-</u>
352	FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank
353	(www.veripalvelu.fi/verenluovutus/biopankkitoiminta), Terveystalo Biobank
354	(www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/) and Arctic Biobank
355	(https://www.oulu.fi/en/university/faculties-and-units/faculty-medicine/northern-finland-
356	birth-cohorts-and-arctic-biobank). All Finnish Biobanks are members of BBMRI.fi
357	infrastructure (<u>www.bbmri.fi</u>). Finnish Biobank Cooperative -FINBB (<u>https://finbb.fi/</u>) is the
358	coordinator of BBMRI-ERIC operations in Finland. The Finnish biobank data can be accessed
359	through the Fingenious [®] services (<u>https://site.fingenious.fi/en/</u>) managed by FINBB.

360

361 FUNDING STATEMENT

Markkinen et al

14

362 The study was supported by funding from the Government of	Finland VTR funding,	
---------------------------------------------------------------	----------------------	--

- 363 Munuaissäätiö (to S. Markkinen) and Suomen Transplantaatiokirurginen yhdistys ry (to S.
- Markkinen), the State Subsidy to Hospitals (TYH2019311 and TYH2022315 to S. Meri),
- 365 Helsinki University Hospital Diagnostic Center funds (Y780023006, to S. Meri) and Sigrid
- 366 Jusélius Foundation (to S. Meri). FinnGen is funded by two grants from Business Finland
- 367 (HUS 4685/31/2016 and UH 4386/31/2016) and twelve industry partners (AbbVie Inc,
- 368 AstraZeneca UK Ltd, Biogen MA Inc, Celgene Corporation, Celgene International II Sarl,
- 369 Genentech Inc, GlaxoSmithKline, Janssen Biotech Inc. Maze Therapeutics Inc., Merck Sharp
- 370 & Dohme Corp, Novartis, Pfizer Inc., Sanofi). The funders and biobanks had no role in study
- design, data collection and analysis, decision to publish, or preparation of the manuscript.
- 372

373 ETHICS STATEMENT

- 374 The study conforms to the principles of the Declaration of Helsinki and has been approved
- by the ethics committee of Helsinki University Hospital (HUS/1873/2018) and the Finnish
- 376 National Supervisory Authority for Welfare and Health (V/9161/2019).

Markkinen et al

377 REFERENCES

378 1. Steers NJ, Li Y, Drace Z, D'Addario JA, Fischman C, Liu L, et al. Genomic Mismatch at 379 LIMS1 Locus and Kidney Allograft Rejection. N Engl J Med. 2019;380(20):1918-28. 380 2. Markkinen S, Helanterä I, Lauronen J, Lempinen M, Partanen J, Hyvärinen K. 381 Mismatches in gene deletions and kidney-related proteins as candidates for 382 histocompatibility factors in kidney transplantation. Kidney Int Reports. 383 2022;7(11):2484-94. 384 3. Võsa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B, et al. Large-scale cis-385 and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that 386 regulate blood gene expression. Nat Genet [Internet]. 2021 Sep 1 [cited 2023 May 11];53(9):1300–10. Available from: https://pubmed.ncbi.nlm.nih.gov/34475573/ 387 388 4. Kwong A, Boughton AP, Wang M, Vandehaar P, Boehnke M, Abecasis G, et al. FIVEx: 389 an interactive eQTL browser across public datasets. Bioinformatics [Internet]. 2022 390 Jan 15 [cited 2023 Oct 27];38(2):559-61. Available from: 391 https://pubmed.ncbi.nlm.nih.gov/34459872/ 392 5. Liu H, Doke T, Guo D, Sheng X, Ma Z, Park J, et al. Epigenomic and transcriptomic 393 analyses define core cell types, genes and targetable mechanisms for kidney disease. 394 Nat Genet [Internet]. 2022 Jul 1 [cited 2023 May 25];54(7):950-62. Available from: 395 https://pubmed.ncbi.nlm.nih.gov/35710981/ 396 6. Lucientes-Continente L, Márguez-Tirado B, Goicoechea de Jorge E. The Factor H 397 protein family: The switchers of the complement alternative pathway. Vol. 313, 398 Immunological Reviews. Immunol Rev; 2023. p. 25-45. 399 7. Rodríguez De Córdoba S, Esparza-Gordillo J, Goicoechea De Jorge E, Lopez-Trascasa 400 M, Sánchez-Corral P. The human complement factor H: Functional roles, genetic variations and disease associations. Mol Immunol [Internet]. 2004 Jun [cited 2023 Sep 401 20];41(4):355–67. Available from: https://pubmed.ncbi.nlm.nih.gov/15163532/ 402 403 8. Meri S, Pangburn MK. Discrimination between activators and nonactivators of the 404 alternative pathway of complement: regulation via a sialic acid/polyanion binding site

Markkinen et al

405		on factor H. Proc Natl Acad Sci U S A [Internet]. 1990 [cited 2023 Nov
406		23];87(10):3982–6. Available from: https://pubmed.ncbi.nlm.nih.gov/1692629/
407 408 409	9.	Meri S. Self-nonself discrimination by the complement system. FEBS Lett [Internet]. 2016 Aug 1 [cited 2023 Nov 23];590(15):2418–34. Available from: https://pubmed.ncbi.nlm.nih.gov/27393384/
410	10.	Närkiö-Mäkelä M, Hellwage J, Tahkokallio O, Meri S. Complement-regulator factor H
411		and related proteins in otitis media with effusion. Clin Immunol [Internet]. 2001 [cited
412		2023 Nov 23];100(1):118–26. Available from:
413		https://pubmed.ncbi.nlm.nih.gov/11414752/
414 415	11.	Malik TH, Lavin PJ, De Jorge EG, Vernon KA, Rose KL, Patel MP, et al. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J Am Soc Nephrol [Internet]. 2012 Jul [cited
416		2023 Nov 2];23(7):1155-60. Available from:
417		https://pubmed.ncbi.nlm.nih.gov/22626820/
418	12.	Józsi M, Licht C, Strobel S, Zipfel SLH, Richter H, Heinen S, et al. Factor H
419		autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3
420		deficiency. Blood [Internet]. 2008 [cited 2023 Nov 9];111(3):1512–4. Available from:
421		https://pubmed.ncbi.nlm.nih.gov/18006700/
422	13.	Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, et al. Association
423		of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with
424		mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic
425		syndrome. Blood. 2010;115(2):379–87.
426	14.	Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, et al. Genome-wide association study
427		identifies susceptibility loci for IgA nephropathy. Nat Genet [Internet]. 2011 Feb [cited
428		2023 Nov 2];43(4):321–9. Available from:
429		https://pubmed.ncbi.nlm.nih.gov/21399633/
430	15.	Roufosse C, Simmonds N, Clahsen-Van Groningen M, Haas M, Henriksen KJ, Horsfield
		Control A 2010 Defension Cuide to the Dewift Classification of Dewal Alle such
431		C, et al. A 2018 Reference Guide to the Banff Classification of Renal Allograft

Markkinen et al

433	16.	Józsi M, Licht C, Strobel S, Zipfel SLH, Richter H, Heinen S, et al. Factor H
434		autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3
435		deficiency. Blood. 2008;111(3):1512–4.
436	17.	Kiryluk K, Novak J. The genetics and immunobiology of IgA nephropathy. J Clin Invest
437		[Internet]. 2014 Jun 2 [cited 2023 Nov 9];124(6):2325–32. Available from:
438		https://pubmed.ncbi.nlm.nih.gov/24892706/
439	18.	Hughes AE, Orr N, Esfandiary H, Diaz-Torres M, Goodship T, Chakravarthy U. A
440		common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower
441		risk of age-related macular degeneration. Nat Genet [Internet]. 2006 Oct [cited 2023
442		Nov 9];38(10):1173–7. Available from: https://pubmed.ncbi.nlm.nih.gov/16998489/
443	19.	Sun Z, Zhang Z, Banu K, Gibson IW, Colvin RB, Yi Z, et al. Multiscale genetic
444		architecture of donor-recipient differences reveals intronic LIMS1 mismatches
445		associated with kidney transplant survival. J Clin Invest [Internet]. 2023 Sep 7 [cited
446		2023 Oct 25]; Available from: https://pubmed.ncbi.nlm.nih.gov/37676733/
447	20.	Thurman JM, Harrison RA. The susceptibility of the kidney to alternative pathway
448		activation-A hypothesis. Immunol Rev [Internet]. 2023 Jan 1 [cited 2023 Nov
449		23];313(1):327–38. Available from: https://pubmed.ncbi.nlm.nih.gov/36369971/
450	21.	Rasmi Y, Jalali L, Khalid S, Shokati A, Tyagi P, Ozturk A, et al. The effects of prolactin on
451		the immune system, its relationship with the severity of COVID-19, and its potential
452		immunomodulatory therapeutic effect. Cytokine [Internet]. 2023 Sep 1 [cited 2023
453		Nov 2];169:156253. Available from: /pmc/articles/PMC10247151/
454	22.	Sellin L, Huber TB, Gerke P, Quack I, Pavenstädt H, Walz G. NEPH1 defines a novel
455		family of podocin interacting proteins. FASEB J. 2003;17(1):115–7.
456		

Markkinen et al

457 Table 1. Characteristics of the study cohort.

Characteristic	All patients, n = 1025	Patients with rs7542235 GG genotype, n = 15	Patients with rs7542235 AA/AG genotype, n = 1010	P-value ^ª
Age (median, range)	57 (18279)	58 (36274)	57 (18279)	0.639 ^c
Sex, n (%)				1^{d}
Male	703 (69)	10 (67)	693 (69)	
Female	322 (31)	5 (33)	317 (31)	
Rejection, n (%)	199 (19)	8 (53)	191 (19)	<0.001 ^d
T cell -mediated, n (%)	178 (17)	6 (75)	172 (90)	
Antibody-mediated, n (%)	21 (3)	2 (25)	19 (10)	
Primary diagnosis, n (%)				
Polycystic kidney disease	202 (20)	3 (20)	199 (20)	1 ^e
Diabetic nephropathy with type diabetes	150 (15)	2 (13)	148 (15)	1 ^e
lgA nephropathy	106 (10)	2 (13)	104 (10)	0.662 ^e
Chronic kidney disease, unspecified	105 (10)	2 (13)	103 (10)	0.660 ^e
Glomerular disorder in amyloidosis	6 (1)	1(7)	5 (1)	0.085 [°]
Glomerular disorder in polyarteritis nodosa	4 (0)	1(7)	3 (0)	0.057 [°]
Glomerular disorder in granulomatosis with polyangiitis	10 (1)	1 (7)	9 (1)	0.137 ^e
Hydronephrosis with ureteropelvic junction obstruction	2 (0)	1 (7)	1 (0)	0.029 ^e
Other chronic kidney disease	22 (2)	1(7)	21 (2)	0.279 ^e
Polycystic kidney disease, unspecified	9 (1)	1(7)	8 (1)	0.124 ^e
Oth er	409 (40)	O (O)	409 (40)	<0.001 ^e
	Me	edian (IQR)		
Death-censored follow-up time, months	37 (18263)	37 (9250)	37 (18263)	0.402 ^c
PRA >0, % ^b	22 (5255)	52 (20264)	21 (5255)	0.290 ^c
PRA >0, % ^b	27 (12260)	17 (17258)	27 (12260)	0.702 ^c
Cold ischemia, hours	20 (17223)	21 (19 2 22)	20 (17223)	0.569 [°]
HLA eplet mismatch sum, n	27 (19236)	28 (17246)	27 (19236)	0.808 ^c
HLA eplet mismatch sum, n	11 (7215)	9 (71213)	11 (7215)	0.459 ^c
HLA eplet mismatch sum, n	16 (7⊡24)	22 (8228)	16 (7224)	0.388 ^c

458 HLA, human leukocyte antigen; IgA, Immunoglobulin A; IQR, interquartile range; PRA, panel-reactive antibody. 459 ^aThe significance of variation was calculated between rs7542235 GG vs. AG/AA groups.

 b The medians of PRA values are calculated only from patients with PRAI >0 and PRAII >0. 460

461 ^cThe Mann–Whitney U-test.

462 ^dThe Pearson chi-square test.

463 ^eFisher's exact test.

^fThe Student's t-test. 464

Markkinen et al

Characteristic	Patients with rs7542235 GG genotype, n = 15	Patients with rs7542235 GG genotype with rejection, n = 8	Patients with rs7542235 GG genotype without rejection, n = 7	P-value ^ª	
Age (median, range)	58 (36-74)	52 (36-73)	61 (53-74)	0.064 ^c	
Sex, n (%)				0.854 ^d	
Male	10 (67)	6 (75)	4 (57)		
Female	5 (33)	2 (25)	3 (43)		
Rejection, n (%)	8 (50)	8 (100)	O (O)		
T cell -mediated, n (%)	6 (38)	6 (75)	O (O)		
Antibody-mediated, n (%)	2 (12)	2 (25)	O (O)		
Primary diagnosis, n (%)					
Polycystic kidney disease	3 (20)	O (O)	3 (43)	0.076 [°]	
Diabetic nephropathy with type I diabetes	2 (13)	1 (12.5)	1 (14)	1 ^e	
lgA nephropathy	2 (13)	2 (25)	0 (0)	0.466 ^e	
Chronic kidney disease, un specified	2 (13)	2 (25)	0 (0)	0.466 [°]	
Glomerular disorder in amyloidosis	1(7)	1 (12.5)	0 (0)	1 ^e	
Glomerular disorder in polyarteritis nodosa	1(7)	0 (0)	1 (14)	0.466°	
Glomerular disorder in granulomatosis with polyangiitis	1 (7)	1(12.5)	0 (0)	1 ^e	
Hydronephrosis with ureteropelvic junction obstruction	1 (7)	O (O)	1(0)	0.466 ^e	
Other chronic kidney disease	1(7)	O (O)	1 (14)	0.466 ^e	
Polycystic kidney disease, unspecified	1(7)	1 (12.5)	0 (0)	1 ^e	
	Mee	dian (IQR)			
Follow-up time, months	37 (9-50)	29 (9-40)	41 (24-70)	0.189 [°]	
PRA >0, % ^b	52 (20-64)	52 (36-62)	36 (22-50)	NA^{f}	
PRA >0, % ^b	17 (17-58)	17 (17-17) ^g	99 (99-99) ^h	NA^{f}	
Cold ischemia, hours	21 (19-22)	22 (19-23)	21 (19-22)	0.491 ^f	
HLA eplet mismatch sum, n	28 (17-46)	38 (23-49)	27 (14-33)	0.182 ^c	
HLA eplet mismatch sum, n	9 (7-13)	12 (7-19)	9 (8-11)	0.521 ^c	
HLA eplet mismatch sum, n	22 (8-28)	23 (14-30)	8 (7-25)	0.269 [°]	

465Table 2. Characteristics of the 15 patients with rs7542235 GG-genotype tagging for homozygous CFHR321466deletion. Rejection vs. non-rejection group.

467 HLA, human leukocyte antigen; IgA, Immunoglobulin A; IQR, interquartile range; PRA, panel-reactive antibody.

^aThe significance of variation was calculated between rejection and non-rejection group of patients with
 rs7542235 GG-genotype.

470 ^bThe medians of PRA values are calculated only from patients with PRAI >0 and PRAII >0.

471 ^cThe Mann–Whitney U-test.

472 ^dThe Pearson chi-square test.

473 ^eFisher's exact test.

474 ^fThe significance of variation was not analyzed due to the low frequency count.

475 ^gn = 2

476 ^hn = 1

477 ^fThe Student's t-test.

Markkinen et al

479 Table 3. Detailed description of serum samples.

Sample ID (pseudonymized)	Sample number in the Figure 4	Pre-tx sample	Post-tx sample	The region for homozygous deletion according to MLPA/WGS	The region for heterozygous deletion according to MLPA/WGS	Rejection*
ABGR4XFUNH	1	x		CFHR3 (exons 126), CFHR1 (exons 126)		0
ABGR4XFUNH	2		x	CFHR3 (exons 1₪6), CFHR1 (exons 1₪6)		0
BCZORKR4A3	3	x		CFHR3 (exons 1₪6), CFHR1 (exons 1₪6)		0
DGYMLR5QCF	4	x		no deletion control sample		0
EN257NXZIH	5	x		CFHR3 (exons 126), CFHR1 (exons 126)		0
NQZTUVJ6JA	6	x		CFHR3 (exons 1⊡6), CFHR1 (exons 1⊡6)		0
3RVWTIW47P	7	x		CFHR3 (exons 1⊡6), CFHR1 (exons 1⊡6)		1
3RVWTIW47P	8		x	CFHR3 (exons 1⊡6), CFHR1 (exons 1⊡6)		1
ADCKGCMCUK	9	x		CFHR3 (exons 1⊡6), CFHR1 (exons 1⊡6)		1
ADCKGCMCUK	10		x	CFHR3 (exons 1⊡6), CFHR1 (exons 1⊡6)		1
JUIHLJXRHX	11	x		CFHR1 (exons 126)	CFHR3 (exons 1⊡6), CFHR4 (exons 1⊡10)	1
JUIHLJXRHX	12		x	CFHR1 (exons 126)	CFHR3 (exons 1⊡6), CFHR4 (exons 1⊡10)	1
QDM 2EBUW CF	13	x		CFHR3 (exons 1⊡6), CFHR1 (exons 1⊡6)		1
QDM 2EBUW CF	14		x	CFHR3 (exons 1₪6), CFHR1 (exons 1₪6)		1
V53C3LDXJW	15	x		CFHR3 (exon 6), CFHR1 (exons 1⊡6)	CFHR3 (exons 1₪4), CFHR4 (exons 1₪6)	1
V53C3LDXJW	16		x	CFHR3 (exon 6), CFHR1 (exons 1⊡6)	CFHR3 (exons 1₪4), CFHR4 (exons 1₪6)	1

480 CFHR, complement factor H related; MLPA, multiplex ligation-dependent probe amplification; WGS, whole

481 genome sequencing; *Acute rejection status 0 = no rejection, 1 = rejection

482

Markkinen et al

483 Table 4. eQTL associations of *CFHR3*21 deletion tagging variant rs7542235.

Gene	Tissue	Chromosome	Assessed allele	Other allele	Effectsize	P-value
CFHR1	blood vessel	1	G	Α	-0.48	7.59 x 10 ⁻⁰⁶
CFHR1	kidn ey	1	G	A	- 1.68	0.00
CFHR1	blood vessel	1	G	A	-0.43	0.02
CFHR1	blood vessel	1	G	A	-0.08	0.35
CFHR3	blood vessel	1	G	A	-0.92	1.17 x 10 ⁻²³
CFHR3	blood vessel	1	G	A	-0.78	1.91 x 10 ⁻¹⁶
CFHR3	blood vessel	1	G	А	-0.96	4.17 x 10 ⁻¹¹
CFHR3	kidn ey	1	G	A	- 1.64	0.00
CFHR4	kidn ey	1	G	A	-0.98	0.02

eQTLGen Consortium

Gene	Tissue	Chromosome	Assessed allele	Other allele	Z-score	P-value
CFH	Blood	1	G	A	10.05	8.88 x 10 ⁻²⁴

Human Kidney eQTL Atlas

Gene	Tissue	Chromosome	Assessed allele	Other allele	Be ta *	P-value
CFHR1	kidney tubule	1	G	А	-0.77	2.73 x 10 ⁻⁵⁸
CFHR3	kidney tubule	1	G	A	- 0. 33	4.01 x 10 ⁻¹⁰

484 *Effect size (Beta) is reported with respect to the alternate allele

485

Table 5. pQTL associations of CFHR321 deletion tagging variant rs7542235 in Olink and SomaScan data.

Markkinen et al

487

22

Olink (n = 1225)									
Gene	Chromosome	Assessed allele	Other allele	Beta	P-value	FDR			
CFH	1	G	A	0.415	2.335 x 10 ⁻¹²	5.794 x 10 ⁻⁰⁸			
CFH R2	1	G	А	0.375	2.542 x 10 ⁻¹⁰	3.154 x 10 ^{.06}			
CFH R5	1	G	А	0.329	2.970 x 10 ⁻⁰⁸	2.457 x 10 ⁻⁰⁴			
		S	iomaScan (n = 86!	5)					
Gene	Chrom oso me	Assessed allele	Other allele	Beta	P-value	FDR			
AKR 1B 10	1	G	А	-0.870	6.008 x 10 ⁻³⁷	2.171 x 10 ⁻³²			
CFH	1	G	А	0.366	1.813 x 10 ^{.07}	0.001			
CFH R1	1	G	А	-0.821	1.053 x 10 ⁻³³	3.803 x 10 ⁻²⁹			
CFH R5	1	G	А	0.402	9.306 x 10 ^{.09}	3.955 x 10 ⁻⁰⁵			
DYNLT3	1	G	А	0.365	1.946 x 10 ^{.07}	0.001			
F13B	1	G	А	0.434	5.307 x 10 ⁻¹⁰	2.950 x 10 ⁻⁰⁶			
GLT8D1	1	G	А	-0.408	5.618 x 10 ^{.09}	2.706 x 10 ⁻⁰⁵			
KIRREL1	1	G	А	0.353	4.784 x 10 ^{.07}	0.002			
LRP1B	1	G	A	-0.344	9.862 x 10 ^{.07}	0.003			
MAN 1B1	1	G	А	0.445	1.969 x 10 ⁻¹⁰	1.294 x 10 ⁻⁰⁶			
MYCT1	1	G	А	-0.327	3.344 x 10 ^{.06}	0.010			
NAGLU	1	G	А	-0.627	1.114 x 10 ^{.19}	1.341 x 10 ⁻¹⁵			
NDUFS4	1	G	А	0.643	1.077 x 10 ⁻²⁰	1.556 x 10 ⁻¹⁶			
OTOR	1	G	А	-0.406	6.562 x 10 ⁻⁰⁹	2.964 x 10 ⁻⁰⁵			
PRLR	1	G	А	-1.029	9.618 x 10 ⁻⁵⁵	6.950 x 10 ^{.50}			
RIPPLY3	1	G	А	0.610	1.142 x 10 ⁻¹⁸	1.179 x 10 ⁻¹⁴			
RPS6KA1	1	G	А	-0.417	2.676 x 10 ^{.09}	1.381 x 10 ⁻⁰⁵			
SCRN3	1	G	A	0.553	1.627 x 10 ⁻¹⁵	1.307 x 10 ⁻¹¹			
TST	1	G	A	0.479	6.902 x 10 ⁻¹²	4.988 x 10 ⁻⁰⁸			
UGT2B15	1	G	A	0.555	1.254 x 10 ⁻¹⁵	1.132 x 10 ⁻¹¹			
ULBP2	1	G	A	0.439	3.291 x 10 ⁻¹⁰	1.981 x 10 ⁻⁰⁶			
ZDHHC4	1	G	А	0.326	3.497 x 10 ⁻⁰⁶	0.010			

488 FDR, false detection rate

Markkinen et al

490 FIGURE LEGENDS

491 Figure 1. MLPA results for rs7542235 GG genotype patients with rejection (A) and without

- 492 rejection (B). Deletion type 1 indicates homozygous deletion at CFHR3 exons (ex) 126 and
- 493 CFHR1 ex 126. Deletion type 2 indicates homozygous deletion at CFHR1 ex 226 and
- heterozygous deletions at *CFHR3* ex 126 and *CFHR4* ex 1210. Deletion type 3 indicates
- 495 homozygous deletion at CFHR3 ex 6 and CFHR1 ex 126 and heterozygous deletions at CFHR3
- 496 ex 124 and CFHR4 ex 126. CFHR, complement factor H related; MLPA, multiplex ligation-
- 497 dependent probe amplification.

498 Figure 2. MLPA results for rs7542235 AA genotype (A) and AG genotype (B) patients.

- 499 Patients with rs7542235 AA genotype had normal genotype without deletions. Patients with
- 500 rs7542235 AG genotype carried a heterozygous deletion covering *CFHR3* ex 1[®]6 and *CFHR1*
- ex 126. CFHR, complement factor H related; MLPA, multiplex ligation-dependent probe
- 502 amplification.


503 Figure 3. Detailed example of MLPA and WGS results for Deletion type 3. Patient with


504 homozygous deletion covering *CFHR3* exon 6 and *CFHR1* exons 126, and heterozygous 505 deletions covering CFHR3 exons 124 and CFHR4 exons 124. A) CFH/CFHR gene locus, exons 506 and deletions of patient V53C3LDXJW. B) MLPA result for the CFH/CFHR locus. The deletion 507 is denoted by the red spots below the deletion cut-off line (red) in the ratio chart. The red 508 line represents the 0.7 ratios, and the blue line represents the 1.3 ratios. Above the blue line 509 are the genes covered by the SALSA MLPA probemix, P236 CFH Region B1. C) Visualization 510 of homozygous deletion in WGS data at the beginning of CFHR3 gene exon 6. Control 511 sample without deletion above, the patient sample below. D) Visualization of heterozygous deletion in WGS data at the end of CFHR4 gene. The coverage (gray) decreases half in size at 512 513 the heterozygous deletion region. CFH, complement factor H; CFHR, complement factor H 514 related; MLPA, multiplex ligation-dependent probe amplification; WGS, whole genome 515 sequencing.

Figure 4. Western blot analyses of CFH, CFHR1 and CFHR2 protein expression. The detailed information for each serum sample is described in Table 3. The sample number 4 (control) and normal human serum (NHS, also control) have normal expression of CFHR1. The other

Markkinen et al

- samples are individuals with homozygous deletion of *CFHR1* gene. CFH, complement factor
- 520 H; CFHR, complement factor H related.





Homozygous Heterozygo deletion deletion

